Dokument: Kognitive Funktionseinschränkungen bei SARS-CoV-2-positiven Personen in häuslicher Isolation und die Korrelation mit depressiven Symptomen und Fatigue
| Titel: | Kognitive Funktionseinschränkungen bei SARS-CoV-2-positiven Personen in häuslicher Isolation und die Korrelation mit depressiven Symptomen und Fatigue | |||||||
| Weiterer Titel: | Cognitive Impairment in SARS-CoV-2-Positive Individuals During Home Isolation and Its Correlation with Depressive Symptoms and Fatigue | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=73953 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20260831-124642-7 | |||||||
| Kollektion: | Dissertationen | |||||||
| Sprache: | Deutsch | |||||||
| Dokumententyp: | Wissenschaftliche Abschlussarbeiten » Dissertation | |||||||
| Medientyp: | Text | |||||||
| Autor: | Seifert, Henning [Autor] | |||||||
| Dateien: |
| |||||||
| Beitragende: | Albrecht, Philipp [Gutachter] Feldt, Torsten [Gutachter] | |||||||
| Stichwörter: | SARS-CoV 2 ,kognitive Einschränkungen,COVID-19,MoCA,BFI,BDI-FS | |||||||
| Dewey Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften » 610 Medizin und Gesundheit | |||||||
| Beschreibungen: | Die häufigsten Allgemeinsymptome von COVID-19 umfassen Fieber, Husten, Schnupfen, Dyspnoe und Fatigue. Zusätzlich wurde von neurologischen Symptomen wie Geruchs- und Geschmacksverlust sowie kognitiven Einschränkungen berichtet. Die Mehrheit der mit SARS-CoV-2 infizierten Personen zeigte lediglich milde respiratorische Symptome, die ambulant behandelt werden konnten. Dennoch klagten auch Betroffene mit mildem Verlauf wiederholt über kognitive Beeinträchtigungen.
Im Rahmen dieser Studie wurde untersucht, ob es bei SARS-CoV-2-positiven Personen während der akuten Erkrankung sowie vier bis sechs Wochen später zu kognitiven Einschränkungen kommt. Zudem wurde geprüft, ob depressive Symptome oder Fatigue die kognitive Leistung beeinflussen. Die Ergebnisse wurden mit denen einer SARS-CoV-2-negativen Kontrollgruppe verglichen. 241 Teilnehmende wurden mittels CLICKDOC©-Videotelefonie zweimal im Abstand von vier bis sechs Wochen getestet. Zum Einsatz kamen das Montreal Cognitive Assessment (MoCA), das Beck Depression Inventory-Fast Screen sowie das Brief Fatigue Inventory. In der akuten Krankheitsphase zeigten sich keine signifikanten Unterschiede in der Kognition zwischen den Gruppen. Nach vier bis sechs Wochen wurde in beiden Gruppen eine kognitive Verbesserung beobachtet, wobei die SARS-CoV-2-negativen Teilnehmenden bessere Leistungen erzielten. Zu beiden Testzeitpunkten lagen die MoCA-Werte im Durchschnitt über dem klinischen Cut-off für kognitive Beeinträchtigung. Depressive Symptome unterschieden sich zwischen den Gruppen zu keinem Zeitpunkt signifikant. Bei SARS-CoV-2-positiven Personen mit depressiver Symptomatik in der Akutphase zeigten sich jedoch Hinweise auf eine kognitive Beeinträchtigung. Eine stärkere Fatigue wurde bei SARS-CoV-2-positiven Teilnehmenden zu beiden Zeitpunkten festgestellt, ohne signifikanten Einfluss auf die kognitive Leistung. Durch die Ergebnisse wird nahegelegt, dass kognitive und affektive Symptome auch bei mildem COVID-19 klinisch relevant sein können und in zukünftigen Forschungs- und Versorgungskonzepten systematisch berücksichtigt werden sollten.Common systemic manifestations of COVID-19 include fever, cough, rhinorrhea, dyspnea, and fatigue. Neurological sequelae such as anosmia, ageusia, and cognitive dysfunction have also been documented. While most individuals with SARS-CoV-2 infection present with mild respiratory symptoms manageable in an outpatient setting, persistent cognitive complaints are frequently reported even after mild disease courses. This study investigated the presence of cognitive impairment in SARS-CoV-2–positive individuals during the acute phase and at a follow-up assessment four to six weeks later. Secondary objectives included evaluating the impact of depressive symptoms and fatigue on cognitive performance. A SARS-CoV-2–negative cohort served as the control group. A total of 241 participants underwent two assessments, four to six weeks apart, via CLICKDOC© videoconferencing. The cognitive domain was evaluated using the Montreal Cognitive Assessment (MoCA), depressive symptoms via the Beck Depression Inventory–Fast Screen, and fatigue using the Brief Fatigue Inventory. During the acute phase, no statistically significant differences in cognitive performance were observed between groups. At follow-up, both cohorts demonstrated improvement; however, the SARS-CoV-2–negative group achieved higher MoCA scores. At both time points, mean MoCA scores were above the clinical threshold for cognitive impairment. Depressive symptomatology did not differ significantly between groups at any assessment. Nevertheless, SARS-CoV-2–positive participants presenting with depressive symptoms during the acute phase exhibited trends toward cognitive impairment. Fatigue severity was consistently higher in the SARS-CoV-2–positive cohort at both time points, without significant correlation with cognitive performance. These findings indicate that even mild COVID-19 may be associated with clinically relevant cognitive and affective disturbances, warranting systematic consideration in future research protocols and post-infection care strategies. | |||||||
| Quelle: | Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020 Feb 20;382(8):727–33.
2. The Government of Hong Kong Special Administrative Region. CHP closely monitors cluster of pneumonia cases on Mainland [Internet]. 2019 [cited 2021 Feb 13]. Available from: https://www.info.gov.hk/gia/general/201912/31/P2019123100667.htm 3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020;395:565–74. 4. World Health Organisation. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) . 2021. 5. WHO-convened global study of origins of SARS-CoV-2: China Part [Internet]. [cited 2023 Sep 6]. Available from: https://www.who.int/publications/i/item/who-convened-global-study-of-origins-of-sars-cov-2-china-part 6. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Vol. 5, Nature Microbiology. Nature Research; 2020. p. 536–44. 7. Lu J, Gu J, Gu J, Li K, Xu C, Su W, et al. COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. Emerg Infect Dis. 2020 Jul 1;26(7):1628–31. 8. Duguid JP. The size and the duration of air-carriage of respiratory droplets and droplet-nuclei. Journal of Hygiene. 1946;44(6):471–9. 9. Hof H, Dörries R, Geginat G, Schlüter D, Wendt C. Medizinische Mikrobiologie. Medizinische Mikrobiologie. Stuttgart: Georg Thieme Verlag; 2017. 10. Li Y, Qian H, Hang J, Chen X, Hong L, Liang P, et al. Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant [Internet]. medRxiv. 52 medRxiv; 2020 [cited 2021 Mar 10]. p. 2020.04.16.20067728. Available from: https://doi.org/10.1101/2020.04.16.20067728 11. Liu L, Li Y, Nielsen P V., Wei J, Jensen RL. Short-range airborne transmission of expiratory droplets between two people. Indoor Air. 2017 Mar 1;27(2):452–62. 12. World Health Organisation. COVID-19 Epidemiological Update [Internet]. 2024 Jul [cited 2024 Jul 30]. Available from: https://www.who.int/publications/m/item/covid-19-epidemiological-update-edition-169 13. WHO. Coronavirus disease (COVID-19) [Internet]. 2023. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/coronavirus-disease-covid-19 14. World Health Organisation. Novel Coronavirus (2019-nCoV) SITUATION REPORT-5. 2020 Jan. 15. World Health Organisation. 2019-nCoV-Ausbruch: erste Fälle in Europa bestätigt [Internet]. Weltgesundheitsorganisation; 2020 [cited 2021 Feb 24]. Available from: https://www.euro.who.int/de/health-topics/health-emergencies/coronavirus-covid-19/news/news/2020/01/2019-ncov-outbreak-first-cases-confirmed-in-europe 16. Johns Hopkins. Mortality Analyses. 2023 [cited 2024 Jul 30]. Coronavirus Resource Center. Available from: https://coronavirus.jhu.edu/data/mortality 17. Robert-Koch-Institut. RKI - Coronavirus SARS-CoV-2 - Epidemiologischer Steckbrief zu SARS-CoV-2 und COVID-19 [Internet]. [cited 2021 Mar 11]. Available from: https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Steckbrief.html;jsessionid=369417CAEA4A6CB168AB6BDCD5C29F05.internet112?nn=13490888#doc13776792bodyText2 18. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet [Internet]. 2020 Feb 15 [cited 2021 Feb 9];395(10223):497–506. Available from: https://isaric.tghn.org/protocols/ 19. odrow, usanne ; Falke, Dietrich; Truyen, we ; chätzel H Kapitel Coronaviren In: Molekulare Virologie. 2010. p. 246–61. 53 20. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome. New England Journal of Medicine. 2003 May 15;348(20):1967–76. 21. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. New England Journal of Medicine. 2003 May 15;348(20):1953–66. 22. Robert-Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2003. 23. Abdallat MM, Abroug F, Al Dhahry SHS, Alhajri MM, Al-Hakeem R, Al Hosani FI, et al. State of knowledge and data gaps of middle east respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr. 2013 Nov 12;5(Outbreaks). 24. Bauerfeind R. Zoonosen. Köln: Deutscher Ärzteverlag; 2016. 25. World Health Organisation RO for the EM. MERS Situation Update. 2020 Dec. 26. World Health Organisation. Middle East respiratory syndrome coronavirus (MERS-CoV) [Internet]. 2018 Mar [cited 2021 Mar 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov) 27. International Committee on Taxonomy of Viruses. ICTV [Internet]. [cited 2021 Mar 1]. Available from: https://talk.ictvonline.org/taxonomy/ 28. Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021 Mar 1;19(3):141–54. 29. Wertheim JO, Chu DKW, Peiris JSM, Kosakovsky Pond SL, Poon LLM. A Case for the Ancient Origin of Coronaviruses. J Virol. 2013 Jun 15;87(12):7039–45. 30. Singh D, Yi S V. On the origin and evolution of SARS-CoV-2. Exp Mol Med. 2021 Apr 1;53(4):537–47. 31. Pagani I, Ghezzi S, Alberti S, Poli G, Vicenzi E. Origin and evolution of SARS-CoV-2. Eur Phys J Plus. 2023 Feb 1;138(2). 32. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. 270 | Nature |. 2012;579. 54 33. Lam TTY, Jia N, Zhang YW, Shum MHH, Jiang JF, Zhu HC, et al. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 2020 583:7815. 2020 Mar 26;583(7815):282–5. 34. Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. 35. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ [Internet]. 2020 Mar 26 [cited 2023 Sep 12];368. Available from: https://www.bmj.com/content/368/bmj.m1091 36. Costa AS, Balloff C, Bungenberg J, Tauber SC, Telke AK, Bandlow C, et al. Cognitive and neuropsychiatric trajectories up to one year after mild to severe COVID-19. Psychiatry Res [Internet]. 2023 Sep 1 [cited 2025 Jan 16];327. Available from: https://pubmed.ncbi.nlm.nih.gov/37523889/ 37. Balloff C, Bandlow C, Bernhard M, Brandenburger T, Bludau P, Elben S, et al. Prevalence and prognostic value of neurological affections in hospitalized patients with moderate to severe COVID-19 based on objective assessments. Sci Rep [Internet]. 2023 Dec 1 [cited 2025 Jan 16];13(1):19619. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10638293/ 38. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA [Internet]. 2020 Mar 3 [cited 2023 Sep 12];323(11):1061. Available from: /pmc/articles/PMC7042881/ 39. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic Features in Severe SARS-CoV-2 Infection. Vol. 382, The New England journal of medicine. 2020. p. 2268–70. 40. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol [Internet]. 2020 Jun 1;77(6):683–90. Available from: https://doi.org/10.1001/jamaneurol.2020.1127 55 41. Kremer S, Lersy F, Anheim M, Merdji H, Schenck M, Oesterlé H, et al. Neurologic and neuroimaging findings in patients with COVID-19. Neurology. 2020 Sep 29;95(13):e1868 LP-e1882. 42. Harapan BN, Hyeon ·, Yoo J. Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol. 2021;268:3059–71. 43. Bauer L, Laksono BM, De Vrij FMS, Kushner SA, Harschnitz O, Van Riel D. The neuroinvasiveness, neurotropism, and neurovirulence of SARS-CoV-2. 2022; 44. Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al. Olfactory transmucosal SARS-CoV-2 invasion as a port of central nervous system entry in individuals with COVID-19. Nat Neurosci. 2021;24(2):168–75. 45. Becker JH, Lin JJ, Doernberg M, Stone K, Navis A, Festa JR, et al. Assessment of Cognitive Function in Patients After COVID-19 Infection. JAMA Netw Open. 2021 Oct 1;4(10):e2130645–e2130645. 46. Alemanno F, Houdayer Id E, Parma A, Spina A, Forno A Del, Scatolini A, et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. 2021 [cited 2024 May 28]; Available from: https://doi.org/10.1371/journal.pone.0246590 47. Amalakanti S, Arepalli KVR, Jillella JP. Cognitive assessment in asymptomatic COVID-19 subjects. Virusdisease [Internet]. 2021 Mar 1 [cited 2024 Feb 3];32(1):146–9. Available from: https://pubmed.ncbi.nlm.nih.gov/33614860/ 48. Berlin RKI. Corona in Zahlen [Internet]. 2023. p. https://www.corona-in-zahlen.de/hospitalisierung/. Available from: https://www.corona-in-zahlen.de/hospitalisierung/ 49. Davis HE, Mccorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology |. 2023;21:133–46. 50. (DGP) DG f. P und B e. V. AWMF S1-Leitlinie Long/ Post-COVID(Version 2.0) [Internet]. 2022. Available from: https://register.awmf.org/de/leitlinien/detail/020-027 56 51. Ceban F, Ling S, Lui LMW, Lee Y, Gill H, Teopiz KM, et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav Immun. 2022;101:93–135. 52. Taquet , eddes JR, Frcpsych H, Harrison PJ, xford ) ;, Harrison PJ, et al 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021;8:416–43. 53. von Etzdorf A, Harzen M, Heinrichs H, Seifert H, Groiß SJ, Balloff C, et al. The population based cognitive testing in subjects with SARS-CoV-2 (POPCOV2) study: longitudinal investigation of remote cognitive and fatigue screening in PCR-positive cases and negative controls OPEN ACCESS EDITED BY. Front Hum Neurosci [Internet]. 2024 [cited 2025 Apr 18];18:1468204. Available from: https://www.cdc.gov/coronavirus 54. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. J Am Geriatr Soc. 2005 Apr 1;53(4):695–9. 55. DeYoung N, Shenal B V. The reliability of the Montreal Cognitive Assessment using telehealth in a rural setting with veterans. J Telemed Telecare. 2019 May 1;25(4):197–203. 56. Chapman JE, Cadilhac DA, Gardner B, Ponsford J, Bhalla R, Stolwyk RJ. Comparing face-to-face and videoconference completion of the Montreal Cognitive Assessment (MoCA) in community-based survivors of stroke. J Telemed Telecare. 2019; 57. Iiboshi K, Yoshida K, Yamaoka Y, Eguchi Y, Sato D, Kishimoto M, et al. A Validation Study of the Remotely Administered Montreal Cognitive Assessment Tool in the Elderly Japanese Population. Telemedicine and e-Health. 2020 Jul 1;26(7):920–8. 58. Radbruch L, Sabatowski R, Elsner F, Everts J, Mendoza T, Cleeland C. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage. 2003 May 1;25(5):449–58. 57 59. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The Rapid Assessment of Fatigue Severity in Cancer Patients Use of the Brief Fatigue Inventory. 1999; 60. Kliem S, Mößle T, Zenger M, Brähler E. Reliability and validity of the beck depression inventory-fast screen for medical patients in the general German population. J Affect Disord. 2014 Mar 1;156:236–9. 61. Poole H, Bramwell R, Murphy P. The utility of the Beck Depression Inventory Fast Screen (BDI-FS) in a pain clinic population. European Journal of Pain. 2009 Sep 1;13(8):865–9. 62. Benedict RHB, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B. Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. http://dx.doi.org/101191/1352458503ms902oa. 2003 Aug 1;9(4):393–6. 63. Beck AT. Beck Depression Iventory-Fast Screen [Internet]. Available from: https://www.testzentrale.de/shop/beck-depressions-inventar-fs.html 64. Elben S, Dimenshteyn K, Trenado C, Folkerts AK, Ophey A, Sulzer P, et al. Screen Fast, Screen Faster: A Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast creen in Parkinson’s Disease ith ild Cognitive Impairment. Front Neurol. 2021 Mar 8;12:640137. 65. Liu YH, Chen Y, Wang QH, Wang LR, Jiang L, Yang Y, et al. One-Year Trajectory of Cognitive Changes in Older Survivors of COVID-19 in Wuhan, China: A Longitudinal Cohort Study. JAMA Neurol [Internet]. 2022 May 1 [cited 2024 May 18];79(5):509–17. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2789919 66. Ermis U, Rust MI, Bungenberg J, Costa A, Dreher M, Balfanz P, et al. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. [cited 2024 Jan 21]; Available from: https://doi.org/10.1186/s42466-021-00116-1 67. Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M, et al. Cognitive impairment and altered cerebral glucose metabolism in the subacute stage of COVID-19. [cited 2024 Mar 25]; Available from: www.mocatest.org 68. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted 58 to ICUs of the Lombardy Region, Italy. JAMA [Internet]. 2020 Apr 28 [cited 2024 May 20];323(16):1574–81. Available from: https://jamanetwork.com/journals/jama/fullarticle/2764365 69. Schilling J, Tolksdorf K, Marquis A, Faber M, Pfoch T, Buda S, et al. The different periods of COVID-19 in Germany: a descriptive analysis from January 2020 to February 2021. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz [Internet]. 2021 Sep 1 [cited 2024 May 21];64(9):1093–106. Available from: https://link.springer.com/article/10.1007/s00103-021-03394-x 70. Khanna S, Khanna N, Malav M, Bayad H, Sood A, Abraham L. Profiling Cognitive Impairment in Mild COVID-19 Patients: A Case-Control Study at a Secondary Healthcare Centre in the Hilly Region of North India. Ann Indian Acad Neurol [Internet]. 2022 Nov 1 [cited 2024 Jan 21];25(6):1099. Available from: /pmc/articles/PMC9996485/ 71. Dressing A, Bormann T, Blazhenets G, Schroeter N, Walter LI, Thurow J, et al. Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome. 2022 [cited 2024 Apr 22]; Available from: https://www.R-project.org/ 72. Hampshire A, Azor A, Atchison C, Trender W, Hellyer PJ, Giunchiglia V, et al. Cognition and Memory after Covid-19 in a Large Community Sample. New England Journal of Medicine [Internet]. 2024 Feb 29 [cited 2024 May 5];390(9):806–18. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2311330 73. Furlan Damiano R, Guedes BF, Castanho de Rocca C, de Pádua Serafim A, Henrique Martins Castro L, Demarchi Munhoz C, et al. Cognitive decline following acute viral infections: literature review and projections for post-COVID-19. 2022 [cited 2024 May 11];272:139–54. Available from: https://doi.org/10.1007/s00406-021-01286-4 74. Davis AG, Dreyer AJ, Albertyn C, Maxebengula M, Stek C, Wasserman S, et al. Cognitive Impairment in Tuberculous Meningitis. 2022 [cited 2024 May 11]; Available from: https://doi.org/10.1093/cid/ciac831 75. Policy Clark MA and A, Korczak MPH VS, Sanderson C, Edmond K, Clark A, Korczak VS, et al. Global and regional risk of disabling sequelae from bacterial 59 meningitis: a systematic review and meta-analysis. Lancet Infect Dis [Internet]. 2010 [cited 2024 May 11]; Available from: www.thelancet.com/ 76. Saiful Islam M, Zannatul Ferdous M, Soumayia Islam U, Syed Md Mosaddek A, Potenza MN, Pardhan S. Treatment, Persistent Symptoms, and Depression in People Infected with COVID-19 in Bangladesh. Int J Environ Res Public Health. 2021;18:1453. 77. Statistisches Bundesamt. Statistisches Bundesamt - Basistabelle Bangladesch [Internet]. [cited 2024 May 18]. Available from: https://www.destatis.de/DE/Themen/Laender-Regionen/Internationales/Staat/Asien/BD.html?view=main[Print] 78. Statistisches Bundesamt. Statistisches Bundesamt - Basistabelle Deutschland [Internet]. [cited 2024 May 18]. Available from: https://www.destatis.de/DE/Themen/Laender-Regionen/Internationales/Staat/Europa/DE.html?view=main[Print] 79. Statistisches Bundesamt. Pressemitteilung Nr. 200 vom 23. Mai 2023. 2023 [cited 2024 May 18]. Gehaltsvergleich 2022:Neben dem Beruf ist der Bildungsschluss entscheidend. Available from: https://www.destatis.de/DE/Presse/Pressemitteilungen/2023/05/PD23_200_62.html 80. Statistisches Bundesamt - Statistisches Bundesamt [Internet]. [cited 2024 Jul 9]. Available from: https://www.destatis.de/DE/Themen/Gesellschaft-Umwelt/Bildung-Forschung-Kultur/Bildungsstand/Tabellen/bildungsabschluss.html?view=main[Print] 81. Carfì A, Bernabei R, Landi F. Persistent Symptoms in Patients After Acute COVID-19. JAMA [Internet]. 2020 Aug 11 [cited 2024 May 27];324(6):603–5. Available from: https://jamanetwork.com/journals/jama/fullarticle/2768351 82. Tenforde MW, Kim SS, Lindsell CJ, Rose EB, Shapiro NI, Clark ; D, et al. Morbidity and Mortality Weekly Report Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network-United States, March-June 2020. 2020 [cited 2024 May 19];69(30). Available from: https://www.cdc.gov/mmwr 83. Sigfrid L, Drake TM, Pauley E, Jesudason EC, Olliaro P, Lim WS, et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. The Lancet Regional 60 Health - Europe [Internet]. 2021 [cited 2024 May 27];8:100186. Available from: http://creativecommons.org/licenses/by/4.0/ 84. Hartung TJ, Neumann C, Bahmer T, Chaplinskaya-Sobol I, Endres M, Geritz J, et al. Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. 2022 [cited 2024 May 19]; Available from: https://doi.org/10.1016/j. 85. Pan Z, Park C, Brietzke E, Zuckerman H, Rong C, Mansur RB, et al. Cognitive impairment in major depressive disorder. 2018 [cited 2024 Jun 1]; Available from: https://doi.org/10.1017/S1092852918001207 86. Halahakoon DC, Lewis G, Roiser JP. Cognitive Impairment and Depression—Cause, Consequence, or Coincidence? JAMA Psychiatry [Internet]. 2019 Mar 1 [cited 2024 Jun 1];76(3):239–40. Available from: https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2719452 87. Brown LA, Ballentine E, Zhu Y, Mcginley EL, Pezzin L, Abramoff B. The unique contribution of depression to cognitive impairment in Post-Acute Sequelae of SARS-CoV-2 infection. 2022 [cited 2024 Jun 1]; Available from: https://doi.org/10.1016/j.bbih.2022.100460 88. Brodaty H, Connors MH, Quinto L. Psychological Medicine Longitudinal outcomes of patients with pseudodementia: a systematic review. 2018 [cited 2025 Jan 12]; Available from: https://doi.org/10.1017/S0033291718002829 89. Mouta S, Fonseca Vaz I, Pires M, Ramos S, Figueiredo D. What do we know about pseudodementia? Gen Psychiatr [Internet]. 2023 Aug 22 [cited 2025 Jan 13];36(4):e100939. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10445398/ 90. Reinhold D, Farztdinov V, Yan Y, Meisel C, Sadlowski H, Kühn J, et al. The brain reacting to COVID-19: analysis of the cerebrospinal fluid proteome, RNA and inflammation. J Neuroinflammation [Internet]. 2023 Dec 1 [cited 2025 Jan 16];20(1):1–16. Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-023-02711-2 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 31.08.2026 | |||||||
| Dateien geändert am: | 31.08.2026 | |||||||
| Promotionsantrag am: | 26.10.2025 | |||||||
| Datum der Promotion: | 09.07.2026 |
